📣In high-risk nonmetastatic upper tract urothelial cancer, neoadjuvant gemcitabine + split-dose cisplatin yields durable benefit. 👉At 7 yrs, responders had DFS 78% vs 31%, CSS 90% vs 56%, OS 87% vs 48%. Supports NAC as standard for high-risk UTUC. OncoAlert ari hakimi

Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?

2/5 KN905 #ESMO25: Perioperative EVP in MIBC shows ⬆️ EFS,OS & pCR vs cystectomy alone in cisplatin ineligible MIBC. Gem/cis durvalumab showed pCR=37% & OS HR of 0.75. Will EVP be much better? Will it only apply to the cisplatin ineligible population? Will we see pembro only arm?

3/5 IMVIGOR011 #ESMO25 Atezo vs placebo in ctDNA+ve UC post cystectomy hit OS/PFS.It also tracks outcomes in the ctDNA-ve supporting a ctDNA adjusted approach, potentially sparing persistently negative patients adjuvant therapy. What is its relevance in the era of perioparive IO?

4/5 #ESMO25 :POTOMAC (Durvalumab/BCG vs BCG alone in MIBC) is +ve for EFS, but is it practice changing? ALBAN trial (atezo/BCG vs BCG in MIBC-result unknown) is also at ESMO. How will they compare with CREST (sasanlimab/BCG). Will there be consistency or a subgroup who benefit?

5/5 #ESMO25 The DISCUS trial randomises 3 vs 6 cycles of chemotherapy+sequenced avelumab in M1 UC. Patient reported outcome is the primary endpoint. 3 cycles is likely to be better tolerated but is efficacy compromised? Does this open the door for shorter period of ADC trials

Probiyotikler ve fitokimyasal zengin beslenme  Prostat kanserini önleyebilir deniztural profdrdeniztural.com/probiyotikler-…

#ASTRO25 Matthew P Deek explored the genomic landscape of oligometastatic PCa: 📌 STOMP & ORIOLE: MDT improves outcomes, but not all benefit equally. 💡 Hypothesis: Metastatic extent + onset are biologically driven / genomics holds the key. 🔎 TP53 & HR mutations = higher risk,

Hormon pozitif meme kanserinde yeni tedavi seçeneği deniztural profdrdeniztural.com/hormon-pozitif…

Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy academic.oup.com/oncolo/article… This multicenter retrospective study of 214 patients with metastatic castration-resistant #ProstateCancer (mCRPC) treated with

FDA 🇺🇸Approval tinyurl.com/4a8jr38b On October 2, 2025, the FDA approved lurbinectedin with atezolizumab as maintenance therapy for adults with extensive-stage small cell lung cancer (ES- #SCLC )that has not progressed after initial atezolizumab-based chemotherapy. In the

Tedavi seçeneği kalmamış Böbrek kanserinde yeni tedavi seçeneği deniztural profdrdeniztural.com/tedavi-seceneg…

Our annual symposium has just started! Koç Üniversitesi Emory University Emory Urology RMK AIMES

As Koç University, we held the third edition of the Sunshine Symposium this year in collaboration with Emory University and Mayo Clinic, bringing together our esteemed uro-oncology faculty members and participants from neighboring countries.

Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early

Great to have Emory Urology wonderful robotic team visiting our training center RMK AIMES in Istanbul! Mohammad Hajiha Vikram M. Narayan, MD This year we have: Intuitive Da Vinci xi & x Medtronic Digital Surgery Hugo RAS robotic systems at our training center Koç Üniversitesi

Annual Sunshine Symposium completed with great success! Emory Urology Koç Üniversitesi Thanks to all participants from Emory University (USA), Azerbaijan, Bulgaria, Serbia, Mongolia, Kosova, Georgia, Iran, Bosnia & Türkiye! Program: urocourse.com/docs/Urocourse…

Great to have you with us Dear colleague Prof deniztural Thanks for your wonderful academic support & sharing your experience & knowledge with us!

Yüksek Doz(mega-doz) Vitamin C kanser Tedavisinde Faydalı mı deniztural profdrdeniztural.com/yuksek-dozmega…

🚨Just in Nature Medicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj Prostate Cancer Foundation OncoAlert UroToday.com